Guggenheim analyst Yatin Suneja lowered the price target on Immunovant (NASDAQ: IMVT) to $48.00 (from $50.00) while maintaining a Buy ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE